Yes. Cyagen provides:

HLA-transgenic models (e.g., HLA-A2) for antigen-specific T-cell responses.
HUGO-GT™ mice with full human gene replacements (e.g., hTCF4 for repeat expansion diseases).
Immune checkpoint humanized models (e.g., hOX40, hPD-1) for IO therapeutic screening.

PBMC models: Ready in 6 weeks with >80% engraftment success.
HSC models: Full reconstitution in 12–16 weeks with >75% success.
Our TurboKnockout® platform accelerates gene-edited model production by 4–6 months vs. traditional ES cell methods.

Cyagen’s huBLT models (bone marrow-liver-thymus engraftment) enhance lymph node organogenesis and antigen presentation. NKG mice express human cytokines (e.g., GM-CSF/IL-3) to support myeloid cell development, overcoming limitations in legacy NSG/NOG models.

Yes. Using HLA-matched donor cells and functional T-cell assays (e.g., PD-1/CTLA-4 expression profiling), our models replicate human-specific cytokine cascades (e.g., IL-6/IL-1β surges), enabling predictive CRS risk assessment for IND submissions.

We guarantee >55% hCD3+ humanization via flow cytometry, ensuring clinical relevance for T-cell-dependent responses. HLA-matched donor cells reduce xenogeneic rejection, and our NKG platform is validated for myeloid/lymphoid lineage development, critical for autoimmune and infectious disease studies.

Cyagen’s NKG immunodeficient mice support dual-engraftment—PBMC transplants enable rapid T-cell studies (2–3 weeks post-transplant) for CAR-T/ICI efficacy, while HSC engraftment achieves stable immune reconstitution (>45 weeks) for chronic disease modeling. This eliminates the need for separate models, streamlining preclinical workflows.